Marqibo Advisory Committee Review Will Consider Benefit Of Partial Response

FDA's Oncologic Drugs Advisory Committee will consider whether partial responses are likely to predict clinical benefit of Inex/Enzon's liposomal vincristine injection for non-Hodgkin's lymphoma at its Dec. 1 meeting. The committee will also consider Marqibo's benefit over existing therapies.